Contact: Vincenzo Bonifati, Department of Clinical Genetics, Erasmus MC Rotterdam, PO Box 1738, 3000 DR Rotterdam, Netherlands T) 00 31 10 408 7583Professor Nicholas W Wood, Department of Molecular Neuroscience, Institute for. Neurology and NationalDepartment of Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK T) 0207 837 3611 William C. Nichols. Cincinnati Children’s Hospital Medical Center, 3333 Burnet Avenue, 1469 TCHRF, Cincinnati, OH 45229, USA T) 513-636-2438.
Could be could be the most important cause of disease susceptibility for Parkinson become identified so far. ‘.. William Nichols and colleagues measured the frequency of the LRRK2 mutation in familial Parkinson ‘s disease by screening the DNA of patients and controls of 767 subjects from 358 families, 35 patients. 20 different families had one or two copies of the mutation and had typical clinical features of Parkinson’s disease suggest results suggest that the single mutation in the LRRK2 gene causes Parkinson’s disease in 5 percent of individuals with the familial form of the disease. Commented commented: ‘Screening for the new mutation is likely to to be an important component of genetic testing for Parkinson’s disease in the near future is important only only been screened for mutations in the LRRK2 gene additional mutation has already been identified.About TIMEthe TIME clinical program utilizes Kosan to the improved, proprietary an injectable suspension formula Tanespimycin. The injectable suspension formulation to stop important benefits, like improved patient safety due to the discontinuation of Cremophore and the allocated need to steroids premedication hypersensitivity. Tanespimycin injectable suspension also an potential increased intellectual property of item and a simpler manufacturing and medicament administered over the prior of the formulation.
Kosan the motilin agonist compound, KOS-2187 licensed Pfizer is to a Phase 1 study at gastroesophageal reflux disease . – For more information on Kosan Biosciences, visit the Web site at.